266 related articles for article (PubMed ID: 31009835)
1. Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysis.
Stevens B; Winters A; Gutman JA; Fullerton A; Hemenway G; Schatz D; Miltgen N; Wei Q; Abbasi T; Vali S; Singh NK; Drusbosky L; Cogle CR; Hammes A; Abbott D; Jordan CT; Smith C; Pollyea DA
Leuk Res; 2019 Jun; 81():43-49. PubMed ID: 31009835
[TBL] [Abstract][Full Text] [Related]
2. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.
DiNardo CD; Daver N; Jabbour E; Kadia T; Borthakur G; Konopleva M; Pemmaraju N; Yang H; Pierce S; Wierda W; Bueso-Ramos C; Patel KP; Cortes JE; Ravandi F; Kantarjian HM; Garcia-Manero G
Lancet Haematol; 2015 Jan; 2(1):e12-20. PubMed ID: 26687423
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study.
Daver N; Garcia-Manero G; Basu S; Boddu PC; Alfayez M; Cortes JE; Konopleva M; Ravandi-Kashani F; Jabbour E; Kadia T; Nogueras-Gonzalez GM; Ning J; Pemmaraju N; DiNardo CD; Andreeff M; Pierce SA; Gordon T; Kornblau SM; Flores W; Alhamal Z; Bueso-Ramos C; Jorgensen JL; Patel KP; Blando J; Allison JP; Sharma P; Kantarjian H
Cancer Discov; 2019 Mar; 9(3):370-383. PubMed ID: 30409776
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
Saygin C; Larkin K; Blachly JS; Orwick S; Ngankeu A; Gregory CT; Phelps MA; Mani S; Walker A; Garzon R; Vasu S; Walsh KJ; Bhatnagar B; Klisovic RB; Grever MR; Marcucci G; Byrd JC; Blum W; Mims AS
Am J Hematol; 2020 Dec; 95(12):1457-1465. PubMed ID: 32777116
[TBL] [Abstract][Full Text] [Related]
5. A systematic review and meta
Kunacheewa C; Thongthang P; Ungprasert P; Utchariyaprasit E; Owattanapanich W
Hematology; 2019 Dec; 24(1):498-506. PubMed ID: 31221030
[TBL] [Abstract][Full Text] [Related]
6. Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia.
Craddock C; Slade D; De Santo C; Wheat R; Ferguson P; Hodgkinson A; Brock K; Cavenagh J; Ingram W; Dennis M; Malladi R; Siddique S; Mussai F; Yap C
J Clin Oncol; 2019 Mar; 37(7):580-588. PubMed ID: 30653424
[TBL] [Abstract][Full Text] [Related]
7. Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome.
Narayan R; Garcia JS; Percival ME; Berube C; Coutre S; Gotlib J; Greenberg P; Liedtke M; Hewitt R; Regan K; Williamson C; Doykan C; Cardone MH; McMillan A; Medeiros BC
Leuk Lymphoma; 2016; 57(3):609-15. PubMed ID: 26374199
[TBL] [Abstract][Full Text] [Related]
8. Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia.
Kenealy M; Hertzberg M; Benson W; Taylor K; Cunningham I; Stevenson W; Hiwase D; Eek R; Zantomio D; Jong S; Wall M; Blombery P; Gerber T; Debrincat M; Zannino D; Seymour JF
Haematologica; 2019 Apr; 104(4):700-709. PubMed ID: 30545923
[TBL] [Abstract][Full Text] [Related]
9. Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia.
Winters AC; Maloney KW; Treece AL; Gore L; Franklin AK
Pediatr Blood Cancer; 2020 Oct; 67(10):e28398. PubMed ID: 32735397
[TBL] [Abstract][Full Text] [Related]
10. A Phase I/II Trial of the Combination of Azacitidine and Gemtuzumab Ozogamicin for Treatment of Relapsed Acute Myeloid Leukemia.
Medeiros BC; Tanaka TN; Balaian L; Bashey A; Guzdar A; Li H; Messer K; Ball ED
Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):346-352.e5. PubMed ID: 29572158
[TBL] [Abstract][Full Text] [Related]
11. Comparison of clinical remission and survival between CLAG and FLAG induction chemotherapy in patients with refractory or relapsed acute myeloid leukemia: a prospective cohort study.
Bao Y; Zhao J; Li ZZ
Clin Transl Oncol; 2018 Jul; 20(7):870-880. PubMed ID: 29181696
[TBL] [Abstract][Full Text] [Related]
12. One plus one does not always equal two, especially with regard to hypomethylating agents: the question of synergy of azacitidine and lenalidomide for treatment of relapsed acute myeloid leukemia and myelodysplastic syndromes post allogeneic hematopoietic stem cell transplant.
Bewersdorf JP; Stahl M; Zeidan AM
Expert Rev Hematol; 2019 Aug; 12(8):575-578. PubMed ID: 31225770
[TBL] [Abstract][Full Text] [Related]
13. Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia.
Medeiros BC; McCaul K; Kambhampati S; Pollyea DA; Kumar R; Silverman LR; Kew A; Saini L; Beach CL; Vij R; Wang X; Zhong J; Gale RP
Haematologica; 2018 Jan; 103(1):101-106. PubMed ID: 29097499
[TBL] [Abstract][Full Text] [Related]
14. Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
Attar EC; Amrein PC; Fraser JW; Fathi AT; McAfee S; Wadleigh M; Deangelo DJ; Steensma DP; Stone RM; Foster J; Neuberg D; Ballen KK
Leuk Res; 2013 Sep; 37(9):1016-20. PubMed ID: 23773898
[TBL] [Abstract][Full Text] [Related]
15. Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL).
Thiel A; Schetelig J; Pönisch W; Schäfer-Eckart K; Aulitzky W; Peter N; Schulze A; Maschmeyer G; Neugebauer S; Herbst R; Hänel A; Morgner A; Kroschinsky F; Bornhäuser M; Lange T; Wilhelm M; Niederwieser D; Ehninger G; Fiedler F; Hänel M; ;
Ann Oncol; 2015 Jul; 26(7):1434-40. PubMed ID: 25922062
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia.
Walker AR; Klisovic RB; Garzon R; Schaaf LJ; Humphries K; Devine SM; Byrd JC; Grever MR; Marcucci G; Blum W
Leuk Lymphoma; 2014 Jun; 55(6):1304-8. PubMed ID: 23952243
[TBL] [Abstract][Full Text] [Related]
17. Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies.
Othus M; Sekeres MA; Nand S; Garcia-Manero G; Appelbaum FR; Erba HP; Estey E
Leukemia; 2019 Feb; 33(2):371-378. PubMed ID: 30315234
[TBL] [Abstract][Full Text] [Related]
18. A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients With Heavily Pretreated Relapsed Lymphoma.
Padrnos L; Ernst B; Dueck AC; Kosiorek HE; Ginos BF; Toro A; Johnston PB; Habermann TM; Leis JF; Mikhael JR; Nowakowski GS; Colgan J; Porrata L; Ansell SM; Witzig TE; Reeder C
Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):664-672.e2. PubMed ID: 30104176
[TBL] [Abstract][Full Text] [Related]
19. Eprenetapopt Plus Azacitidine in
Cluzeau T; Sebert M; Rahmé R; Cuzzubbo S; Lehmann-Che J; Madelaine I; Peterlin P; Bève B; Attalah H; Chermat F; Miekoutima E; Rauzy OB; Recher C; Stamatoullas A; Willems L; Raffoux E; Berthon C; Quesnel B; Loschi M; Carpentier AF; Sallman DA; Komrokji R; Walter-Petrich A; Chevret S; Ades L; Fenaux P
J Clin Oncol; 2021 May; 39(14):1575-1583. PubMed ID: 33600210
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities.
Chen Y; Kantarjian H; Estrov Z; Faderl S; Ravandi F; Rey K; Cortes J; Borthakur G
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):341-4. PubMed ID: 22579233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
